CancerNetwork® Weekly Review: July 19, 2021


Every Monday, CancerNetwork® highlights the most important content from the previous week in oncology news.

Recently, Athenex met with the FDA regarding its combination of oral paclitaxel and enequidar to treat patients with metastatic breast cancer. In addition, the latest issue of the journal ONCOLOGY® presented a case of a patient with prostate cancer, as well as a brief review of the origins of COVID-19.

Athenex Discusses Deficiencies Of Oral Paclitaxel Plus Encequidar For Metastatic Breast Cancer At FDA Type A Meeting

The additional data and analyzes on patient subgroups helped Athenex shed a more detailed view of the risks and benefits associated with the combination of oral paclitaxel and enequidar in patients with breast cancer. metastatic. The pharmaceutical company also suggested collecting more overall survival data to better inform the design of a new clinical trial.

The FDA recommended that Athenex implement a “well-designed and well-conducted” clinical trial to address these shortcomings, with the full response letter specifically suggesting risk mitigation strategies, such as dose optimization or exclusion criteria, to improve toxicities for patients. Athenex plans to announce plans for an updated clinical trial that will be presented to the FDA in late 2021.

Shaji Kumar, MD, details the toxicities of daratumumab plus lenalidomide / dexamethasone in first-line MM

CancerNetwork® met with Shaji Kumar, MD, Mayo Clinic, at the 2021 European Hematology Association Congress to discuss the long-term toxicities associated with daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in multiple myeloma newly diagnosed. Kumar mentioned that no new safety signals were detected during the 5-year follow-up of the phase 3 MAIA trial (NCT02252172).

Urethral midlobe embolism after focal ablation of Gleason 7 prostate cancer

This is the case of a 56-year-old man who experienced urinary intermittence, frequency, urgent urination and dysuria 5 months after undergoing focal laser ablation (FLA) for prostate cancer. (PC) of Gleason 3 + 4 = 7.

To the knowledge of the investigators, this is the first case of intermittent urethral obstruction by a scaling of the midlobe of the prostate after ALF. FLA is an emerging therapy for inferior or intermediate CP. The case highlights the need for continuous evaluation of the long-term results of this procedure.

Questions remain about the origin of COVID-19

We may never know where this virus came from. What we do know for sure is that the incredible strength and collaboration of the scientific community has enabled us to regain some semblance of normalcy. The development and deployment of several effective vaccine options has been the medical miracle of our lives.

Tanios S. Bekaii-Saab, MD, discusses key findings from a genomic and immune profiling study in intrahepatic cholangiocarcinoma

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, of the Mayo Clinic, about key findings from a profiling study genomics and immunity in patients with intrahepatic cholangiocarcinoma. Specifically, it examines the impact of IDH1 / 2 mutations and key discoveries linked to these genetic abnormalities.

For more updates from CancerNetwork®, be sure to follow us on Facebook, Twitter, and LinkedIn to stay up to date on the latest news in oncology.



Source link

Previous PBG BioPharma Inc. Receives Cannabis Processing License From Health Canada
Next Baltazard Solvyns etchings from the 1790s place "The Hindus" in Delhi

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *